NeoGenomics Inc

NEO

Company Profile

  • Business description

    NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. The company operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.

  • Contact

    9490 NeoGenomics Way
    Fort MyersFL33912
    USA

    T: +1 239 768-0600

    E: [email protected]

    https://www.neogenomics.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Diagnostics & Research

    Fiscal Year End

    31 December 2026

    Employees

    2,500

Stocks News & Analysis

stocks

Lowering profit forecasts on Aussie airlines

The impact of the oil price surge.
stocks

AI isn’t an economic moat killer, but it will disrupt industries

How we’re rethinking companies’ competitive advantages in an AI-first world.
stocks

AI lands a blow on some Aussie stocks – yet stands to benefit others

AI is reshaping ASX tech moats - but some are more insulated than others.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,745.3066.700.77%
CAC 407,825.6681.741.06%
DAX 4022,905.97269.061.19%
Dow JONES (US)46,435.09311.030.67%
FTSE 10010,080.89115.731.16%
HKSE25,335.95272.241.09%
NASDAQ21,947.40185.500.85%
Nikkei 22553,749.621,497.342.87%
NZX 50 Index12,929.30227.551.79%
S&P 5006,596.4940.120.61%
S&P/ASX 2008,534.3045.700.54%
SSE Composite Index3,931.8450.561.30%

Market Movers